and fluid balance. We analysed whether the level of residual renal function (RRF) in peritoneal dialysis (PD) patients has an impact on the effect of a sodium reduced PDF on blood pressure (BP). METHODS: This is a post-hoc analysis of a prospective, randomized, controlled double-blind clinical study on a low Na PDF (125 mmol/L Na) compared to a standard Na PDF (134 mmol/L Na) (Rutkowski et al. Am J Kidney Dis 2015). Patients in the per protocol population were divided into subgroups according to glomerular filtration rate (GFR) at baseline (&#8804; / > 6 ml/min/1.73 m 2 ). Linear mixed models were used to analyse the interaction between GFR and the effect of the low Na PDF on BP and on further parameters related to the effect of sodium balance after 12 weeks of exposure following the initial analysis of this study. Estimation of the treatment effect was adjusted for baseline levels, country, GFR subgroup and the interaction between treatment and GFR subgroup; clustering of patients within study centres was accounted for by a random centre effect. Treatment effects on antihypertensive medication from baseline to week 12 were analysed by use of a Wilcoxon rank sum test. RESULTS: Out of the analysis population (82 pts), 52 had a GFR &#8804; 6 ml/min/ 1.73 m 2 and 30 a GFR > 6 ml/min/1.73 m 2 at baseline. In the low GFR group the systolic BP was reduced with low Na PDF from 152624 mmHg at baseline to 137621 mmHg at week 12. Diastolic BP decreased from 90616 mmHg to 83611 mmHg. In the standard sodium group and in patients with high GFR in both treatment groups only minor changes were observed. For the low GFR subgroup, the treatment group difference in systolic BP at week 12 predicted by the linear mixed model was -16.9 (95% CI -27.16 to -6.64) mmHg. For diastolic BP, the difference was -7.92 (95% CI -12.62 to -1.43) mmHg, and after exclusion of two highly influential observations (sensitivity analysis), it was -4.58 (95% CI -10.07 to 0.91). In the high GFR group, no statistically significant difference of BP between the two solutions was observed. Antihypertensive medication increased slightly in all groups, to a lesser extent in the low Na PDF group. CONCLUSIONS: Sodium reduction in the PDF supports sodium and fluid balance (as shown in the primary study analysis -reduced serum Na, thirst, water intake, fluid output (urine and ultrafiltration)), likely generating a new steady state. The resulting reduction of BP in the low Na PDF group seems to be more effective in patients with no or low RRF than in patients with a residual capacity of renal sodium and fluid control.
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FP473 DOES PERITONEAL DIALYSIS VINTAGE AFFECT

INTRODUCTION AND AIMS:
Leucocyte telomere length (LTL) is an emerging novel biomarker of ageing and survival. Oxidative stress and chronic inflammation have been associated with progressive telomere loss. Telomere shortening to a critical limit is associated with replicative senescence and cell death. Current data in peritoneal dialysis (PD) cohort suggests that adjusted all-cause mortality is associated with dialysis vintage. All the current literature on LTL and dialysis vintage has been investigated in haemodialysis patients with conflicting results but none have reported LTL outcomes in PD cohorts. The aim of our study was to investigate if PD vintage is associated with LTL and 1 year mortality outcome. METHODS: We conducted a single centre prospective cohort study. All eligible PD patients who have been established on dialysis were recruited and blood samples taken as per study protocol. Whole blood was immediately isolated for peripheral blood mononuclear cells which were analysed for relative telomere length (rTL) by quantitative real-time polymerase chain reaction (rt-PCR) according to a modified Cawthon protocol. rTL was expressed in the form of T/S ratio. Baseline demographic data and dialysis vintage were obtained from the electronic patient record. RESULTS: A total of 105 patients (68 male, 37 female) were recruited from May 2016 to February 2017. Age ranged from 23 to 82 with a median age of 56. Dialysis vintage for this cohort ranged from 7 to 547 weeks with a median of 81 weeks. Mean rTL reported as T/S ratio in this cohort was 2.136. Mean C-reactive protein, a marker of inflammation was 8. (normal <5). rTL was inversely associated with age. (r¼ -0.443, p< 0.01). rTL was also increased in women in comparison to men and this was statistically significant. (p¼0.044) Correlation between dialysis vintage and rTL approached statistical significance, however this association was diminished when adjusted for age and sex. (p¼ 0.060) rTL had no correlation with all-cause mortality outcome in this cohort. (r¼ -0.168, p¼0.088). We were unable to show any significant association between dialysis vintage with 1 year mortality outcome. (p¼ 0.073) CONCLUSIONS: To our knowledge, this is the largest study in a PD cohort investigating the role of LTL and dialysis vintage. Our findings revealed that no association was found between dialysis vintage in PD patients and rTL; a biomarker of ageing. A hypothesis to explain the lack of association when compared to some of the haemodialysis literature is that excess accumulation of oxidative products and inflammation is less in PD cohort in comparison to haemodialysis cohort due to the nature of the dialysis modality. Larger, longer term studies are warranted to validate the findings of this study. þ should have a diffusion capacity (MTAC, KBD, PS) close to 17 mL/min which is more than twice than that estimated using 'low-sodium' dialysis fluids (~8 mL/min) and 4-5 times more than that obtained using standard fluids (4-5 mL/min). Although several explanations have been proposed for this difference in transport, the exact mechanisms involved have remained unknown. METHODS: In the current investigation a new model, based on the 3-pore model, is developed for the transport of small charged molecules across the peritoneum during PD. The flow of the charged solutes across a pore system is modeled by a modified NernstPlanck equation. Analysis of clinical data is performed using the novel model by means of repeated non-linear regression to fit both ion transport data and intra-peritoneal volume data. In addition, results from a simulated 24-hour dwell study are presented. RESULTS: It is shown that the difference between the measured and the theoretically expected diffusive transport of several ions during PD can be almost completely explained by electro-diffusive forces acting over the peritoneal barrier which are caused by the difference in permeability of the different charged molecular species present in the plasma and dialysate. Especially, it is predicted that the presence of anionic plasma proteins with low permeability to the peritoneal cavity represents an important factor for ion transport. Furthermore, it is demonstrated that, although the direction of the electrical field is usually such that the potential in the peritoneal cavity is positive relative to the circulation, the flows of both anionic and cationic species can potentially be hindered by the transport of counter-ions in a phenomenon called 'counter-ion limited transport'. After 24-hours, the dialysate concentrations of small ionic species are predicted to be very close to the theoretical Gibbs-Donnan equilibrium concentrations.
FP474 WHY IS THE DIFFUSION OF SODIUM AND CALCIUM SO POOR IN PERITONEAL DIALYSIS? ANALYSIS OF CLINICAL SODIUM AND CALCIUM DATA USING A MODIFIED 3-PORE MODEL
CONCLUSIONS:
In conclusion, the current results indicate that the transport of small ionic species during peritoneal dialysis is influenced by electrical forces. These novel insights have important implications for our understanding of the physiology of the peritoneal membrane and the complex forces that determine the transport of charged small solutes during PD. 
Abstracts
Nephrology Dialysis Transplantation is a soluble iron salt approved to maintain iron balance and hemoglobin in patients receiving chronic hemodialysis. FPC donates iron to transferrin, bypassing the reticuloendothelial block to iron metabolism. FPC added to peritoneal dialysis fluid (PDF) may replace and/or maintain iron stores. METHODS: Thirty (30) PD patients were enrolled in an open-label, randomized, twoperiod, single ascending dose study of FPC administered in PDF. All patients received FPC in either Dianeal V R (1.5% dextrose) 2 L or Extraneal V R (Icodextrin 7.5%), 1.5 L for a 12 hour dwell. FPC was delivered in PDF at iron concentrations of 2.5; 5.0 (2 cohorts); 7.5 or 12.5 mg Fe/L. At a separate session, 6.5 mg FPC was administered IV over 4 hours. A serum iron profile (sFe) was obtained to characterize the pharmacokinetics (PK) of of absorbed iron. RESULTS: Iron absorption from PDF was dose dependent with peak sFe at approximately 6 hours. Clearance of PD iron followed a similar time course as IV FPC administration. Serum iron levels exhibited an initial rapid rise followed by a slower increase that is likely due to lymphatic absorption.PDF IL-6 was increased in all PD samples compared to baseline or with PDF after 6.5 mg FPC-IV. The increase was highest in the 12.5 mg Fe/L cohort but variable in the other doses. IL-10, MCP-1 Hyaluronin (HA) and CA-125 were also elevated with no clear dose response. The results were highly variable among patients.Triferic was well tolerated. Four patients (13%) experienced moderate abdominal discomfort and cramping on infusion of the 12.5 and 7.5 mg dose. Transient nausea and vomiting occurred in 2 patients (7%) upon infusion of PDF. One subject withdrew. No changes in PDF cell counts or differential were observed at any dose level. CONCLUSIONS: Ferric pyrophosphate citrate (FPC, TrifericV R ) is bioavailable via peritoneal dialysis. The adverse effects were mild to moderate in severity and appeared to be dose dependent. Iron was absorbed from PDF to the systemic circulation by diffusion and lymphatic transport. Serum iron was rapidly cleared with a time course similar to IV FPC.FPC has a different cytokine profile when added to PDF than via HD or IV. Since PDF lacks transferrin, FPC iron may enter cells via non-transferrin pathways. The resulting cytokine profile is pro-inflammatory both in-vivo and ex-vivo with elevations in IL-6, Il-10 and HA. The significant variation in the individual reaction to PDF FPC means that some patients may be more prone to stress effects of FPC at the level of the peritoneum. Changes in intraperitoneal cytokines when FPC is administered via peritoneal dialysis merit further investigation. FPC added to PDF may be an effective and simple iron replacement therapy for PD patients.
FP476 DOES PERITONEAL DIALYSIS REALLY INTENSIFY THE CARBOHYDRATE EXCHANGE DISORDERS IN NONDIABETIC PATIENTS?
Natalia Stepanova 
INTRODUCTION AND AIMS:
Peritoneal dialysis (PD) solutions using glucose as osmotic agent have been used for more than two decades as effective treatment for patients with end-stage renal disease. Although alternative osmotic agents such as amino acids and macromolecular solutions, including polypeptides and glucose polymers, are now available, glucose is still the most widely used osmotic agent in PD. It has been shown to be safe, effective, readily metabolized, and inexpensive. On the other hand glucose absorption from the peritoneal cavity may lead to the development of insulin resistance (IR). The aim of our study was to investigate the impact of PD initiation on the carbohydrate exchange disorders in non-diabetic end-stage renal disease (ESRD) patients. METHODS: A total of 15 patients with ESRD, who started treatment with continuous ambulatory peritoneal dialysis (CAPD) have been included in this longitudinal, observational cohort study. All patients were male, (the average age 49.6 6 5.9). Treatment with CAPD was performed using Dianeal PD 4 with a glucose concentration of 1.36% and 2.27% (Baxter Healthcare Corporation, USA). Patients were screened before initiation of PD, in 3 and 12 months of treatment. All patients were determined for the insulin, leptin and C-peptide blood levels using ELISA-method. The concentration of insulin was analyzed using antibodies against the human insulin molecule using the DRG Instruments GmbH (Germany) reagents. The Flexor junior biochemical analyser (The Netherlands) was used to study glucose. The insulin resistance index (HOMA-IR) (Homeostatic Model Assessment), which is characterized by the degree of insulin resistance, was calculated by the formula: level of insulin onset (lSO / ml) Â blood glucose onset (mmol / l) / 22.5. The IR was diagnosed with a HOMA index value of ! 2.77 unit. For the statistical analysis we used MedCalc. The normal distribution of data was verified using the Shapiro-Wilks criterion. The average values (M) and standard deviation (SD) or the median (Me) and interquartile ranges [Q25-Q75] were calculated according to a normal distribution. The Mann-Whitney (U) and Student's t-criterion were used to compare them. RESULTS: Among all ESRD patients examined before PD initiation significant increase of carbohydrate exchange rates investigated was shown. After 3 months of PD treatment inspected patients' blood insulin had decreased whereas leptin and C-peptide levels hadn't changed significantly. HOMA-IR after PD initiation had dropped by 63 % (tabl. 1). CONCLUSIONS: PD treatment during 12 months significantly reduces insulin resistance level in CKD stage V paients. Further research are needed to identify the influence of longterm treatment with glucose-containing solutions onto IR state among PD patients. 
Peritoneal dialysis (PD) effluent represents a rich source of molecular markers as novel tools for predicting clinical outcome and monitoring the therapy. Novel PD-fluids may enable patient-tailored interventions, such as peritoneal immunomodulation. High performance chromatographic and mass spectrometric methods allow assessment of molecular changes and therefore detection of candidate biomarkers from the abundant effluent. For understanding PD related processes on a systems biology level, a multi-level omics approach is particularly attractive. METHODS: The commercially available AbsoluteIDQV R p180 Kit (Biocrates, Austria) was used for metabolomic profiling of PD effluent of 20 stable PD patients obtained during a two-period, cross-over RCT (Eudract-2010-022804-29) . PD patients were treated either with standard PD fluid (Dianeal 3.86%, Baxter-Healthcare) or PDprotec TM (Dianeal with added alanyl-glutamine). The obtained metabolomic data were combined in a bioinformatic workflow with proteomic data from our recently established CPLL-FASP-TMT-LC/MS workflow in a multi-omics analysis for PD effluent from the same clinical samples. RESULTS: 188 small molecules, including free amino acids, acylcarnitines and glycerophospholipids, as well as custom metabolic indicators calculated from these metabolites were surveyed in a high throughput assay and correlated to treatment in the crossover trial and patient characteristics, such as time on PD therapy use of icodextrin and previous peritonitis. Together with proteomic data from 2506 individual proteins, coregulated biological processes such as oxidative stress responses were identified. Treatment with cytoprotective PD-protec TM rescued processes thought to be involved in decline of PD treatment efficiency and failing immune response. CONCLUSIONS: Metabolomic profiling of PD effluent proved to be a valuable approach for revealing small molecule related changes during PD treatment. The intervention with PD-protec TM as a cytoprotective PD-fluid does not only restore important immune processes, it is further reflected on small molecule responses such as indicators of oxidative stress in accordance with processes on the protein level. The exploitation of PD effluent information on multiple omics levels as identified by our bioinformatic approach has been shown to improve our understanding of the molecular processes in the peritoneal cavity and their role in development of complications for ultimately improving PD therapy. 
